J Korean Med Sci.  2020 Sep;35(38):e343. 10.3346/jkms.2020.35.e343.

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis

• Sohn KM
• Lee SG
• Kim HJ
• Cheon S
• Jeong H
• Lee J
• Kim IS
• Silwal P
• Kim YJ
• Paik S
• Chung C
• Park C
• Kim YS
• Jo EK

• KMID: 2507100
• DOI: http://doi.org/10.3346/jkms.2020.35.e343

Abstract

Background
Observational studies of the ongoing coronavirus disease 2019 (COVID-19) outbreak suggest that a ‘cytokine storm’ is involved in the pathogenesis of severe illness. However, the molecular mechanisms underlying the altered pathological inflammation in COVID-19 are largely unknown. We report here that toll-like receptor (TLR) 4-mediated inflammatory signaling molecules are upregulated in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients, compared with healthy controls (HC).
Methods
A total of 48 subjects including 28 COVID-19 patients (8 severe/critical vs. 20 mild/ moderate cases) admitted to Chungnam National University Hospital, and age/sex-matched 20 HC were enrolled in this study. PBMCs from the subjects were processed for nCounter Human Immunology gene expression assay to analyze the immune related transcriptome profiles. Recombinant proteins of severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) were used to stimulate the PBMCs and monocyte-derived macrophages, and real-time polymerase chain reaction was performed to quantify the mRNA expressions of the proinflammatory cytokines/chemokines.
Results
Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels. We also observed that recombinant S2 and nucleocapsid proteins of SARS-CoV2 significantly increased proinflammatory cytokines/chemokines and S100A9 in human primary PBMCs.
Conclusion
These data support a link between TLR4 signaling and pathological inflammation during COVID-19 and contribute to develop therapeutic approaches through targeting TLR4-mediated inflammation.

Keyword

SARS-CoV-2; Inflammation; Cytokines; S100A9

Figure

• 

  Fig. 1 Transcriptome analysis reveals that immune gene expression profiles of COVID-19 patients are distinct to HC. (A) Schematic diagram of the immune transcriptome analysis in this study. (B) A result of principal component analysis of log2-transformed 579 immune gene expression levels. (C) The scatter plots representing 579 immune genes with the log2-transformed FPKM for COVID-19 patients compared to HC. (D) The ten most significantly enriched KEGG pathways of the 298 DEiGs from COVID-19 patients compared to HC. (E) Log2-transformed fold changes of chemokine and chemokine receptor genes from MILD (x-axis) and SEVERE (y-axis) vs. HC. (F) Expression levels (FPKM) of marked chemokines in (E). Error bar indicates standard error of mean. P values were calculated using Mann-Whitney U test and adjusted P values (FDR) were shown.COVID-19 = coronavirus disease 2019, HC = healthy controls, FPKM = fragments per kilobase exon-model per million reads mapped, KEGG = Kyoto Encyclopedia of Genes and Genomes, DEiG = differentially expressed immune gene, MILD = mild/moderate, SEVERE = severe/critical, FDR = false discovery rate, IBD = inflammatory bowel disease, TNF = tumor necrosis factor, CCL = C-C motif chemokine ligand, CXCL = C-X-C motif chemokine ligand.*P < 0.05; **P < 0.01; ***P < 0.001.

• 

  Fig. 2 COVID-19 infection boosts NF-κB signaling pathway. (A) The left (MILD) and right (SEVERE) sides of box represent the mean fold change in mRNA levels, compared with HC. The NF-κB signaling pathway was adopted from KEGG database (accession number: hsa04064). (B) The expression levels of IRF3, TLR3, TLR7, TLR8 and TLR9 were represented by FPKM. Error bar indicates standard error of mean. P values were calculated using Mann-Whitney U test and adjusted P values (FDR) were shown.COVID-19 = coronavirus disease 2019, NF = nuclear factor, MILD = mild/moderate, SEVERE = severe/critical, HC = healthy controls, KEGG = Kyoto Encyclopedia of Genes and Genomes, FPKM = fragments per kilobase exon-model per million reads mapped, FDR = false discovery rate, TLR = toll-like receptor, IRF = interferon regulatory factor.*P < 0.05.

• 

  Fig. 3 Top 10 most significantly up- and down-regulated DEiGs in SEVERE patients. (A) Log2-transformed fold changes of 579 immune-genes from MILD vs. HC (x-axis) and SEVERE vs. HC (y-axis). The genes for red and blue colors indicate up- and down-regulated DEiGs in SEVERE patients, respectively. (B, C) Comparisons of expression levels of top 10 up- (B) and down- (C) regulated DEiGs. The expression level was represented by FPKM. (D) Correlation analysis between S100A9 expression level and serum albumin in MILD and SEVERE patients. Error bar indicates standard error of mean. P values were calculated using Mann-Whitney U test and adjusted P values (FDR) were shown (B, C) and Spearman's correlation is shown (D).DEiG = differentially expressed immune gene, MILD = mild/moderate, SEVERE = severe/critical, HC = healthy controls, FPKM = fragments per kilobase exon-model per million reads mapped, FDR = false discovery rate, CCL = C-C motif chemokine ligand, CXCL = C-X-C motif chemokine ligand.*P < 0.05; **P < 0.01; ***P < 0.001.

• 

  Fig. 4 Recombinant NC and S2 ECD proteins of SARS-CoV-2 robustly induce the expression of pro-inflammatory cytokines/chemokines in human primary PBMCs. (A) Schematic diagram of interaction between host cell and SARS-CoV-2 antigen. (B, C) RT-qPCR analysis of indicated genes in human primary PBMCs treated with recombinant NC, S2 ECD, S1 subunit, or RBD antigen (B) and NC or S2 ECD (C) (2 μg/mL each; for 6 hours). (D) Level of IL-6 in cell supernatant from (B) measured by ELISA. (E) Immunoblot analysis of phospho-p65 (NF-κB) in human primary PBMCs treated with S2 ECD (2 μg/mL) for indicated time. (F) RT-qPCR analysis of IL1B in human primary PBMCs treated with recombinant S2 ECD in presence or absence of indicated doses of S100A9 for 6 hours. Welch's t-test (B-D) and One-way analysis of variance (F) were used to measure the significance. Values are mean ± standard deviation. from a representative of two independent experiments performed in triplicate (B, C, F) or mean ± standard error of mean. of pooled data from two independent experiments (D).NC = nucleocapsid, S = spike, ECD = extracellular domain, SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2, PBMC = peripheral blood mononuclear cell, RT-qPCR = real-time quantitative polymerase chain reaction, RBD = receptor binding domain, IL = interleukin, ELISA = enzyme-linked immunosorbent assay, NF = nuclear factor, IFN = interferon, CCL = C-C motif chemokine ligand, CXCL = C-X-C motif chemokine ligand, RBD = receptor binding domain, UN = untreated.*P < 0.05; **P < 0.01; ***P < 0.001.

Reference

1. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020; 201(11):1380–1388. PMID: 32275452.

2. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020; 55(6):2000562. PMID: 32269086.

3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–1062. PMID: 32171076.

4. World Health Organization. Coronavirus disease (COVID-19) pandemic. Updated 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

5. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020; 75(7):1564–1581. PMID: 32396996.

6. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288(2):192–206. PMID: 32348588.

7. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620–2629. PMID: 32217835.

8. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94:91–95. PMID: 32173574.

9. Henry BM, de Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7):1021–1028. PMID: 32286245.

10. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10(2):102–108. PMID: 32282863.

11. Yang Y, Xiao Z, Ye K, He X, Sun B, Qin Z, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020; 17(1):117. PMID: 32727485.

12. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2):281–292.e6. PMID: 32155444.

13. Bhatnager R, Bhasin M, Arora J, Dang AS. Epitope based peptide vaccine against SARS-CoV2: an immune-informatics approach. J Biomol Struct Dyn. 2020; 1–16.

14. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48):eabc8413. PMID: 32527802.

15. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity. JCI Insight. 2020; 142386. PMID: 32796155.

16. World Health Organization. Clinical Management of COVID-19: Interim Guidance, 27 May 2020. Geneva: World Health Organization;2020.

17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. PMID: 31986264.

18. Kim JK, Lee HM, Park KS, Shin DM, Kim TS, Kim YS, et al. MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2. Autophagy. 2017; 13(2):423–441. PMID: 27764573.

19. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res. 2019; 47(D1):D786–92. PMID: 30304474.

20. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191–2194. PMID: 24141714.

21. Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020; 52(5):731–733. PMID: 32325025.

22. Boo KH, Yang JS. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med J. 2010; 51(1):9–17. PMID: 20046508.

23. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005; 560:11–18. PMID: 15932016.

24. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19. J Korean Med Sci. 2020; 35(13):e142. PMID: 32242348.

25. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033–1034. PMID: 32192578.

26. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020; ciaa270. PMID: 32173725.

27. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 71(15):762–768. PMID: 32161940.

28. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):761–770. PMID: 32228226.

29. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020; 5(49):eabd1554. PMID: 32651212.

30. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16–34. PMID: 21235323.

31. Arpaia N, Barton GM. Toll-like receptors: key players in antiviral immunity. Curr Opin Virol. 2011; 1(6):447–454. PMID: 22440908.

32. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373–384. PMID: 20404851.

33. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFκB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol. 2006; 72(9):1102–1113. PMID: 16930560.

34. Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol Med. 2007; 13(11):460–469. PMID: 18029230.

35. Ge Y, Huang M, Yao YM. Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis. Cytokine Growth Factor Rev. 2019; 45:24–34. PMID: 30587411.

36. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003–1018. PMID: 24332029.

37. Chen JQ, Szodoray P, Zeher M. Toll-like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol. 2016; 50(1):1–17. PMID: 25687121.

38. Keogh B, Parker AE. Toll-like receptors as targets for immune disorders. Trends Pharmacol Sci. 2011; 32(7):435–442. PMID: 21529972.

39. Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK, et al. Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Invest. 2018; 128(5):1852–1866. PMID: 29611822.

40. Tomonobu N, Kinoshita R, Sakaguchi M. S100 soil sensor receptors and molecular targeting therapy against them in cancer metastasis. Transl Oncol. 2020; 13(4):100753. PMID: 32193075.

41. Nukui T, Ehama R, Sakaguchi M, Sonegawa H, Katagiri C, Hibino T, et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem. 2008; 104(2):453–464. PMID: 18044712.

42. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018; 9:1298. PMID: 29942307.

43. Leth-Larsen R, Zhong F, Chow VT, Holmskov U, Lu J. The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology. 2007; 212(3):201–211. PMID: 17412287.

44. Guo G, Ye S, Xie S, Ye L, Lin C, Yang M, et al. The cytomegalovirus protein US31 induces inflammation through mono-macrophages in systemic lupus erythematosus by promoting NF-κB2 activation. Cell Death Dis. 2018; 9(2):104. PMID: 29367719.

45. Duette G, Pereyra Gerber P, Rubione J, Perez PS, Landay AL, Crowe SM, et al. Induction of HIF-1α by HIV-1 infection in CD4⁺ T cells promotes viral replication and drives extracellular vesicle-mediated inflammation. MBio. 2018; 9(5):e00757-18. PMID: 30206166.

46. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson J, Mafham M, Bell J, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020; NEJMoa2021436.

47. Bhattacharyya S, Zhao Y, Kay TW, Muglia LJ. Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci U S A. 2011; 108(23):9554–9559. PMID: 21606371.

48. Chinenov Y, Rogatsky I. Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signaling network. Mol Cell Endocrinol. 2007; 275(1-2):30–42. PMID: 17576036.

49. Hoebe K, Jiang Z, Georgel P, Tabeta K, Janssen E, Du X, et al. TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Curr Pharm Des. 2006; 12(32):4123–4134. PMID: 17100615.